Overview

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).
Phase:
Phase 3
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost